Assessing the health burden of a rare, multisystem autoimmune disease

An epidemiological analysis of comorbidities in ANCA-associated vasculitis

Shifa Sarica, Corri Black, Angharad Marks, Lars Peter Erwig, Neil Basu

Research output: Contribution to conferencePoster

Abstract

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) encompasses a heterogeneous group of rare, multisystem autoimmune disorders. Improved treatment regimens have increased patient longevity and inevitably shifted the burden experienced by AAV patients. Comorbidities are increasingly identified as drivers of premature mortality and increased health burden in AAV patients. However, studies on comorbidities in AAV are confined to secondary analysis of clinical trial data and small studies from tertiary care centres. There is a need for comprehensive population-based assessment of comorbidities in AAV patients to attain a clear understanding of the true health burden of AAV. This study aims to (i)contextualise comorbidities in AAV patients by comparing the prevalence of comorbidities in AAV patients to a reference population, and (ii)explore potential risk factors associated with the most common comorbidities. The Primary Care Clinical Informatics Unit (PCCIU) database provides a representative sample of patients from participating Scottish general practices. Read codes were used to identify AAV patients (n: 360, 50.3% male) and five corresponding age- (± 5 years), sex- and general practice-matched controls for each AAV patient. Data on demographics, selected common comorbidities and medications were retrieved for each participant. Descriptive statistics will be used to describe the study participants according to AAV type, demographics and comorbidities. Conditional logistic regression will be carried out to quantify differences between AAV patients and general population controls. Cox proportional hazard regression models, if applicable, will be conducted to identify potentially modifiable risk factors for comorbidities. The data is in the analysis stage, and future plans include conducting a comprehensive data linkage of a population-based AAV cohort with Scottish national databases which would enable robust assessment of comorbidities in AAV. It is anticipated that the results of this study would provide a greater understanding of the evolving health burden of AAV, and may subsequently inform clinical decision-making.
Original languageEnglish
Publication statusUnpublished - 2015
EventThe Farr Institute PhD Symposium - Manchester, United Kingdom
Duration: 9 Jun 201510 Jun 2015

Conference

ConferenceThe Farr Institute PhD Symposium
CountryUnited Kingdom
CityManchester
Period9/06/1510/06/15

Fingerprint

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Vasculitis
Autoimmune Diseases
Comorbidity
Antibodies
Health
General Practice
Demography
Databases
Population
Patient Advocacy
Medical Informatics
Premature Mortality
Population Control
Information Storage and Retrieval

Cite this

Sarica, S., Black, C., Marks, A., Erwig, L. P., & Basu, N. (2015). Assessing the health burden of a rare, multisystem autoimmune disease: An epidemiological analysis of comorbidities in ANCA-associated vasculitis. Poster session presented at The Farr Institute PhD Symposium, Manchester, United Kingdom.

Assessing the health burden of a rare, multisystem autoimmune disease : An epidemiological analysis of comorbidities in ANCA-associated vasculitis. / Sarica, Shifa; Black, Corri; Marks, Angharad; Erwig, Lars Peter; Basu, Neil.

2015. Poster session presented at The Farr Institute PhD Symposium, Manchester, United Kingdom.

Research output: Contribution to conferencePoster

Sarica, S, Black, C, Marks, A, Erwig, LP & Basu, N 2015, 'Assessing the health burden of a rare, multisystem autoimmune disease: An epidemiological analysis of comorbidities in ANCA-associated vasculitis' The Farr Institute PhD Symposium, Manchester, United Kingdom, 9/06/15 - 10/06/15, .
Sarica S, Black C, Marks A, Erwig LP, Basu N. Assessing the health burden of a rare, multisystem autoimmune disease: An epidemiological analysis of comorbidities in ANCA-associated vasculitis. 2015. Poster session presented at The Farr Institute PhD Symposium, Manchester, United Kingdom.
Sarica, Shifa ; Black, Corri ; Marks, Angharad ; Erwig, Lars Peter ; Basu, Neil. / Assessing the health burden of a rare, multisystem autoimmune disease : An epidemiological analysis of comorbidities in ANCA-associated vasculitis. Poster session presented at The Farr Institute PhD Symposium, Manchester, United Kingdom.
@conference{897557f5cfb94a578499cc71001c5f97,
title = "Assessing the health burden of a rare, multisystem autoimmune disease: An epidemiological analysis of comorbidities in ANCA-associated vasculitis",
abstract = "Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) encompasses a heterogeneous group of rare, multisystem autoimmune disorders. Improved treatment regimens have increased patient longevity and inevitably shifted the burden experienced by AAV patients. Comorbidities are increasingly identified as drivers of premature mortality and increased health burden in AAV patients. However, studies on comorbidities in AAV are confined to secondary analysis of clinical trial data and small studies from tertiary care centres. There is a need for comprehensive population-based assessment of comorbidities in AAV patients to attain a clear understanding of the true health burden of AAV. This study aims to (i)contextualise comorbidities in AAV patients by comparing the prevalence of comorbidities in AAV patients to a reference population, and (ii)explore potential risk factors associated with the most common comorbidities. The Primary Care Clinical Informatics Unit (PCCIU) database provides a representative sample of patients from participating Scottish general practices. Read codes were used to identify AAV patients (n: 360, 50.3{\%} male) and five corresponding age- (± 5 years), sex- and general practice-matched controls for each AAV patient. Data on demographics, selected common comorbidities and medications were retrieved for each participant. Descriptive statistics will be used to describe the study participants according to AAV type, demographics and comorbidities. Conditional logistic regression will be carried out to quantify differences between AAV patients and general population controls. Cox proportional hazard regression models, if applicable, will be conducted to identify potentially modifiable risk factors for comorbidities. The data is in the analysis stage, and future plans include conducting a comprehensive data linkage of a population-based AAV cohort with Scottish national databases which would enable robust assessment of comorbidities in AAV. It is anticipated that the results of this study would provide a greater understanding of the evolving health burden of AAV, and may subsequently inform clinical decision-making.",
author = "Shifa Sarica and Corri Black and Angharad Marks and Erwig, {Lars Peter} and Neil Basu",
year = "2015",
language = "English",
note = "The Farr Institute PhD Symposium ; Conference date: 09-06-2015 Through 10-06-2015",

}

TY - CONF

T1 - Assessing the health burden of a rare, multisystem autoimmune disease

T2 - An epidemiological analysis of comorbidities in ANCA-associated vasculitis

AU - Sarica, Shifa

AU - Black, Corri

AU - Marks, Angharad

AU - Erwig, Lars Peter

AU - Basu, Neil

PY - 2015

Y1 - 2015

N2 - Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) encompasses a heterogeneous group of rare, multisystem autoimmune disorders. Improved treatment regimens have increased patient longevity and inevitably shifted the burden experienced by AAV patients. Comorbidities are increasingly identified as drivers of premature mortality and increased health burden in AAV patients. However, studies on comorbidities in AAV are confined to secondary analysis of clinical trial data and small studies from tertiary care centres. There is a need for comprehensive population-based assessment of comorbidities in AAV patients to attain a clear understanding of the true health burden of AAV. This study aims to (i)contextualise comorbidities in AAV patients by comparing the prevalence of comorbidities in AAV patients to a reference population, and (ii)explore potential risk factors associated with the most common comorbidities. The Primary Care Clinical Informatics Unit (PCCIU) database provides a representative sample of patients from participating Scottish general practices. Read codes were used to identify AAV patients (n: 360, 50.3% male) and five corresponding age- (± 5 years), sex- and general practice-matched controls for each AAV patient. Data on demographics, selected common comorbidities and medications were retrieved for each participant. Descriptive statistics will be used to describe the study participants according to AAV type, demographics and comorbidities. Conditional logistic regression will be carried out to quantify differences between AAV patients and general population controls. Cox proportional hazard regression models, if applicable, will be conducted to identify potentially modifiable risk factors for comorbidities. The data is in the analysis stage, and future plans include conducting a comprehensive data linkage of a population-based AAV cohort with Scottish national databases which would enable robust assessment of comorbidities in AAV. It is anticipated that the results of this study would provide a greater understanding of the evolving health burden of AAV, and may subsequently inform clinical decision-making.

AB - Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) encompasses a heterogeneous group of rare, multisystem autoimmune disorders. Improved treatment regimens have increased patient longevity and inevitably shifted the burden experienced by AAV patients. Comorbidities are increasingly identified as drivers of premature mortality and increased health burden in AAV patients. However, studies on comorbidities in AAV are confined to secondary analysis of clinical trial data and small studies from tertiary care centres. There is a need for comprehensive population-based assessment of comorbidities in AAV patients to attain a clear understanding of the true health burden of AAV. This study aims to (i)contextualise comorbidities in AAV patients by comparing the prevalence of comorbidities in AAV patients to a reference population, and (ii)explore potential risk factors associated with the most common comorbidities. The Primary Care Clinical Informatics Unit (PCCIU) database provides a representative sample of patients from participating Scottish general practices. Read codes were used to identify AAV patients (n: 360, 50.3% male) and five corresponding age- (± 5 years), sex- and general practice-matched controls for each AAV patient. Data on demographics, selected common comorbidities and medications were retrieved for each participant. Descriptive statistics will be used to describe the study participants according to AAV type, demographics and comorbidities. Conditional logistic regression will be carried out to quantify differences between AAV patients and general population controls. Cox proportional hazard regression models, if applicable, will be conducted to identify potentially modifiable risk factors for comorbidities. The data is in the analysis stage, and future plans include conducting a comprehensive data linkage of a population-based AAV cohort with Scottish national databases which would enable robust assessment of comorbidities in AAV. It is anticipated that the results of this study would provide a greater understanding of the evolving health burden of AAV, and may subsequently inform clinical decision-making.

M3 - Poster

ER -